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prevented cell invasion in vitro and in vivo. In the absence 
of AHR agonists, the overexpressed AHR protein was pre-
dominantly localized in the cytoplasm, where it interacted 
with vimentin and functioned as an E3 ubiquitin ligase. A 
6-h incubation with the proteasome inhibitor MG-132 fully 
rescued vimentin from AHR-mediated proteasomal degra-
dation. In AHR-overexpressing H1299 cells, either vimen-
tin degradation or invasive suppression could be reversed 
when glycogen synthase kinase 3 beta (GSK3β) was inac-
tivated by CHIR-99021 treatment. In contrast, silencing of 
AHR in A549 cells (AHR highly expressed, weakly inva-
sive) resulted in the downregulation of epithelial biomarkers 
(E-cadherin and claudin-1), augmentation of mesenchymal 
vimentin level, and GSK3β Ser-9 hyper-phosphorylation, 
which led to enhanced invasiveness. This work demon-
strates that cytoplasmic, resting AHR protein may act as an 
EMT suppressor via a non-genomic pathway. Depletion of 
cytoplasmic AHR content represents a potential switch for 
EMT, thereby leading to the scattering of tumor cells.
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Abbreviations
AHR  Aryl hydrocarbon receptor
EMT  Epithelial–mesenchymal transition
GSK3β  Glycogen synthase kinase 3 beta
NSCLC  Non-small cell lung cancer
JAM-1  Junction adhesion molecule-1
ZO-1  Zonula occludens-1
TCDD  2,3,7,8-Tetrachlorodibenzo-p-dioxin
B(a)P  Benzo(a)pyrene
CYP1A1  Cytochrome P450 1A1
MMP  Matrix metalloproteinase
Abstract Aryl hydrocarbon receptor (AHR), a ligand-
activated transcription factor, has been studied extensively 
in carcinogenesis through the genomic pathway. In recent 
years, AHR has also been reported to exert positive or nega-
tive effects on epithelial–mesenchymal transition (EMT), 
the crucial step in tumor malignant progression. However, 
the detailed mechanism remains controversial. Analysis of 
AHR-expression levels in non-small cell lung cancer cell 
lines and lung cancer tissues revealed an inverse correla-
tion between AHR protein levels and tumor cell invasion 
and metastasis. Overexpression of wild-type AHR in H1299 
cells (AHR poorly expressed, potently invasive) not only 
accelerated mesenchymal vimentin degradation, but also 
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Lung cancer, predominantly non-small cell lung carcinoma 
(NSCLC), is an aggressive malignant disease with high 
morbidity and mortality in the world. Although a number 
of treatment options are improving continuously, unfortu-
nately, the prognoses are still unfavorable. The poor prog-
noses are highly associated with the acquired resistance of 
tumor against chemotherapy or targeted therapies. Among 
the various proposed mechanisms for chemoresistance in 
tumor cells, metastatic behavior has been reported to be 
critical (Atmaca et al. 2015).
Epithelial–mesenchymal transition (EMT) is a funda-
mental process that governs embryonic development. This 
transition is characterized by profound phenotypic disrup-
tion in intercellular adhesion. In most cases, this is medi-
ated by SNAI2/SLUG-dependent transcriptional repres-
sion of epithelial signatures (e.g., E-cadherin). In parallel, 
migratory and invasive properties are gained by enhanced 
expression of mesenchymal factors such as α-smooth mus-
cle actin, vimentin, fibronectin, and matrix metalloprotein-
ases (MMPs). To date, it is believed that EMT processes 
are involved during the malignant conversion of epithelial 
tumors (Rico-Leo et al. 2013). During EMT, cancer cells 
not only de-differentiated to fibroblastoid, stem cell-like 
phenotypes with high motility, and invasive properties, but 
also increased production of extracellular matrix to modify 
tumor microenvironment.
Aryl hydrocarbon receptor (AHR) is a ligand-activated 
transcriptional regulator, a member of the basic helix-
loop-helix/Per-Arnt-Sim (bHLH/PAS) family. It is ubiq-
uitously expressed in multiple organs and tissues. The 
PAS region responds to its ligands, many of which are 
environmental toxins, such as 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD), halogenated aromatic hydrocarbons 
(HAHs), and benzo(a)pyrene (B[a]P). In the absence of 
ligands, AHR is sequestered in the cytosol by forming 
a hetero-complex with heat-shock protein 90 (Hsp90) 
through both the bHLH and PAS regions. Upon ligand 
binding, AHR rapidly escapes from its chaperones and 
translocates into the nucleus, where it dimerizes with 
AHR nuclear translocator (ARNT) and recruits a set of 
coactivators and/or corepressors. Eventually, a battery of 
AHR-target genes with xenobiotic-responsive elements 
(XREs, with the core sequences 5′-T/GCGTG-3′) in their 
promoter region is induced. Most of them are xenobiotic-
metabolizing enzymes (e.g., cytochrome P450 1A1), 
which are involved in the biotransformation or detoxi-
fication of harmful xenobiotics (Fan et al. 2010). Fur-
ther, the metabolism of many pro-carcinogens to active 
intermediates via an AHR-dependent genomic pathway 
that results in DNA adduct formation, mutagenesis, and 
tumorigenesis has been well characterized (Ikuta et al. 
2009; Safe et al. 2013).
Abnormal expression or activity of AHR has been high-
lighted in malignant tumor progression in the past few 
years. AHR immunoreactivity analysis of tissues from can-
cer patients revealed increased expression levels of AHR in 
breast (Saito et al. 2014), esophageal (Zhang et al. 2012), 
gastric (Peng et al. 2009b), pancreatic (Koliopanos et al. 
2002), prostate (Richmond et al. 2014), lung (Su et al. 
2013; Portal-Nuñez et al. 2012), liver (Liu et al. 2013), 
and urothelial carcinoma (Ishida et al. 2010) as well as 
glioblastomas (Gramatzki et al. 2009), as compared to its 
expression in surrounding normal tissues. In most cases, 
high AHR expression is found in the nucleus and signifi-
cantly correlates with the histological grade. However, in 
esophageal, pancreatic, and breast tumors, AHR is local-
ized in the cytoplasm and the AHR-expressing status is 
inversely correlated with the histological grade of patients. 
The complex pattern of AHR expression and localization 
in tissues with different malignancies raised our interest to 
investigate the function of AHR in EMT regulation.
It has been previously reported that exposure to AHR 
agonists such as TCDD results in the upregulation of 
snail, slug, and mesenchymal biomarkers (e.g., MMP-2, 
MMP-9, fibronectin, and vimentin), whereas epithelial 
biomarkers (e.g., claudin-1 and E-cadherin) are down-
regulated (Peng et al. 2009a; Ishida et al. 2010; Belguise 
et al. 2007). These changes are not observed in AHR-
KO mice or by pretreatment with AHR-specific siRNA 
(Pierre et al. 2014), suggesting that the transactivation of 
AHR is necessary for EMT. Besides the genomic path-
way described above, ligand binding also activates non-
genomic pathways (defined as AHR dependent, but ARNT 
independent), which lead to Src kinase activation and cell 
migration (Randi et al. 2008; Tomkiewicz et al. 2013). 
However, whether the cytoplasmic, resting (unliganded) 
form of AHR regulates EMT has never been studied. 
Toward this end, we engineered a NSCLC cell line H1299 
(AHR deficient, potently invasive) to express AHR con-
stitutively. Subsequently, we detected the overexpressed 
AHR protein in the cytosol, where the AHR–vimentin 
complex was formed, leading to vimentin degradation via 
the proteasome pathway. In contrast, when AHR expres-
sion was knocked-down in the A549 cell (AHR highly 
expressed, weakly invasive), transformation to a more 
aggressive phenotype was observed. Thus, we concluded 





Cell culture, plasmids, and transfection
Human NSCLC cell lines, A549 and H1299, were pur-
chased from American Type Culture Collection (ATCC; 
Manassas, VA) and were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) as described previously 
(Liu et al. 2014). The CL1-0 and CL1-5 cells are sub-
lines, derived from human lung adenocarcinoma tissues, 
according to the differences in metastatic potential. Both 
sublines were gifts from Dr. Huei-Wen Chen (National 
Taiwan University, Taipei, Taiwan) and were maintained 
in RPMI-1640 media supplemented with 10 % FBS (Liu 
et al. 2014).
The plasmid expressing wild-type hAHR was constructed 
by using pcDNA™ 3.1/V5-His TOPO® TA expression kit 
(Invitrogen, Carlsbad, CA). The insertion sequence of hAHR 
(Gene ID: 196; NCBI reference sequence: NM_001621.4) 
was obtained by PCR with the primer set (sense: ATGAA 
CAGCAGCAGCGCCAAC; antisense: TTACAGGAATC 
CACTGGATGT). For transient transfection, cells were 
seeded at a density of 5 × 105 cells/well. After an overnight 
incubation, pcDNA3.1 or pcDNA3.1-AHR was introduced 
into cells by using Turbofect transfection reagent and manu-
facturer’s recommended protocol (Thermo Scientific™).
For hAHR silencing, the pLKO.1-puro vector 
(TRCN0000021254 and TRCN0000021258), which 
expressed a small hairpin RNA (shRNA) specific to hAHR 
sequences CCCACAACAATATAATGTCTT and CGGCAT-
AGAGACCGACTTAAT, respectively, was purchased from 
RNAi core of Academia Sinica (Taipei, Taiwan). The stabi-
lized AHR-silenced A549 clone was obtained after a 2-week 
puromycin (1 μg/mL) selection.
Cell invasion assay
Twenty-four hours after transfection, cells were 
detached from culture plates. Subsequently, 0.2 mL of 
the cell suspension (5 × 105 cells/mL) was added to the 
upper chamber of transwell with 8-μm pore size (Corn-
ing, New York, NY, USA). Transwell was precoated with 
0.1 mL diluted Matrigel™ (1:4 dilution with serum-free 
DMEM) (BD Biosciences, Belford, MA). Then, culture 
medium was added to the lower chamber. After 24-h 
incubation at 37 °C, cells were fixed with 3.7 % formal-
dehyde and stained in 0.1 % crystal violet for 15 min, 
and non-migratory cells were removed by scraping the 
upper surface of the chamber membrane. The invasive 
cells were counted under a light microscope (Ishida 
et al. 2015).
MTT colorimetric assay
The growth curves of distinct cells were determined by the 
effective reduction of the tetrazolium dye, 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
formazan (Tsai et al. 2015).
Western blot analysis
Whole-cell extracts were prepared by scraping in 0.2–
0.3 mL of RIPA lysis buffer as described earlier (Tsai et al. 
2015). Nuclear and cytoplasmic fractions were harvested 
by using the Nuclear Extract Kit and following the manu-
facturer’s instructions (Active Motif, Carlsbad, CA). Pro-
tein concentrations were determined by Bradford method 
(BioRad, Hercules, CA). Equal amounts of protein from 
each treatment were diluted with loading buffer, boiled, and 
separated on 10 or 15 % gels by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Then, 
the separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes. After a short blocking with 
non-fat milk, the membranes were probed with appropri-
ate primary antibodies, including AHR, ARNT (Santa 
Cruz), vimentin, β-catenin, N-cadherin, E-cadherin, clau-
din-1 (Genetex), occludin (Proteintech), ZO-1 (Invitrogen), 
lamin A/C, GSK3β phospho-Ser-9 and phospho-Tyr-216, 
GSK3β (Epitomics), and β-actin (Sigma), followed by an 
incubation with horseradish peroxidase-conjugated second-
ary antibodies. Immunocomplexes were visualized using 
the enhanced chemiluminescence (ECL) detection reagent 
(Millipore). Band intensities were determined by densi-
tometry analysis using Gel-Pro Analyzer software (Media 
Cybernetics, Warrendale, PA).
Reverse transcription polymerase chain reaction
Total RNA samples (3 μg), which extracted with a com-
mercial kit from Roche (Germany), were converted into 
complementary DNA sequences (cDNA) by MMLV Super-
Script II transcriptase (Epicentre, Madison, WI). Then, 
resultant cDNA was used as a template in a PCR using Taq 
polymerase mixture. The following amplification condi-
tions were used: an initial denaturation at 95 °C for 5 min, 
followed by 25–30 cycles of denaturation at 95 °C for 30 s, 
annealing at 60 °C for 30 s, and extension at 72 °C for 
1 min, followed by a final extension at 72 °C for 10 min. 
PCR products were resolved on a 2 % agarose gel and visu-
alized by ethidium bromide staining. Band intensities were 
determined by densitometry analysis in Gel-Pro Analyzer 
software (Media Cybernetics, Warrendale, PA). β-Actin or 
GAPDH mRNA was used as a normalization control. The 
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forward and reverse primers used in this study are pre-
sented in supplementary Table 1.
Immunofluorescence staining
Cells were grown on glass coverslips to 70 % confluence. 
After treatment, samples were washed twice with PBS 
and fixed in 4 % paraformaldehyde for 15 min. Then, 
cells were permeabilized with 0.1 % Triton X-100 for 
10 min, followed by 10-min incubation with 5 % horse 
serum for blocking non-specific epitopes. AHR localiza-
tion was detected with an anti-AHR antibody (Santa Cruz, 
sc-74571), whereas normal mouse IgG was used as control 
antibody. After an overnight incubation at 4 °C, samples 
were washed routinely with PBS and then incubated with 
fluorescein-conjugated secondary antibody at room temper-
ature for 1 h. 4′,6-Diamidino-2-phenylindole (DAPI) was 
used for nuclear staining. Finally, samples were mounted 
and images were taken using a Zeiss fluorescence micro-
scope (Carl Zeiss, Jena, Germany).
Luciferase reporter assay
Cells were transfected with 2 μg pGL4.43[luc2P/XRE/
Hygro] vector (Promega, Madison, WI) and 0.5 μg of 
pRK5-LacZ, as described earlier. After 24-h transfection, 
cells were exposed to B(a)P for 6–12 h. Subsequently, cell 
extracts were harvested. The luciferase activity was meas-
ured using the Promega reporter assay system. Luciferase 
activities were normalized to transfection efficiency using 
the pRK5-LacZ values.
Immunoprecipitation
Whole-cell lysates were precleared by a short incuba-
tion with protein A magnetic beads (Millipore). Then, the 
lysates (1 mg) were subjected to immunoprecipitation by 
the addition of 1 μg/mL of the following captured anti-
bodies: anti-AHR (Santa Cruz, sc-74571) or antivimen-
tin (Genetex, GTX100619) and incubated overnight with 
end-on-end rotation at 4 °C. This was followed by shaking 
with 50-μL protein A magnetic beads for another 2 h. The 
captured immunocomplexes were precipitated and washed 
3 times with RIPA buffer prior to the addition of 100 μL 
of 2 × SDS sample buffer and heating at 95 °C for 5 min. 
Samples were separated by 10 % SDS-PAGE and analyzed 
as described earlier (Li et al. 2014).
Lung colonization assay
C57BL/6 J mice (4–6 week old, male) were obtained from 
National Taiwan University Animal Center and housed 
aseptically in the animal facility. Mice had free access to 
water and rodent chow. All experimental procedures were 
performed in accordance with the Guide for the Care and 
Use of Laboratory Animals and were approved by the 
IACUC. The metastatic potential evaluation in vivo was 
conducted as described previously (Liu et al. 2014). Briefly, 
single-cell suspensions prepared in serum-free DMEM 
(2.5 × 105 cells/mL) were injected into the tail vein of 
C57BL/6 J mice (0.2 mL/mice). Thirty days later, the mice 
were anesthetized with isoflurane and killed. The lungs 
were fixed with Bouin’s solution, and metastatic colonies 
on the lung surface were counted macroscopically.
Immunohistochemical (IHC) analysis
Human lung cancer tissue microarray (CCA4 E65) was 
purchased from Pantomics (Richmond, CA). The slides 
were stained for AHR at the Department of Pathology, 
National Taiwan University Hospital, according to their 
standard operation protocol. The tissue specimen grades, 
as well as the immunoreactive score, were confirmed by an 
experienced pathologist (Dr. Yi-Jen Peng, Department of 
Pathology, Tri-Service General Hospital, National Defense 
Medical Center, Taipei, Taiwan).
Statistical analysis
All data are expressed as mean ± standard deviation 
(N ≥ 3). One-way analysis of variance (ANOVA) was 
adopted for statistical analysis among groups. The statisti-
cal differences between the control and individual testing 
conditions were analyzed by Student’s t test. p values of 
<0.05 were considered statistically significant.
Results
A low AHR‑expression level in human lung cancer 
tissues/cells is significantly associated with its 
malignancy
Correlation between AHR expression and tumor clinico-
pathological features was analyzed in lung cancer tissues 
of 26 male and 4 female patients, the results of which are 
summarized in Table 1. Representative images of AHR 
immunohistochemistry staining are shown in supple-
mentary Fig. 1. While no statistically significant correla-
tion was found between AHR expression and parameters 
related to age (p = 0.366), gender (p = 0.661), histologi-
cal grade (p = 0.878), and regional lymph nodes metastasis 
(p = 0.88), the metastatic status of tissues showed a signifi-
cant correlation (p = 0.018) with AHR-expression levels.
The invasive potential of human NSCLC cell lines was 
evaluated using Matrigel-precoated transwell inserts. The 
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significantly higher counts of invaded cells obtained for 
H1299 as compared to A549 cells reflect the potent inva-
sive ability of these cells (Fig. 1a). The mRNA and protein 
expression levels of AHR and epithelial–mesenchymal bio-
markers were analyzed, and the representative images are 
presented in Fig. 1b. In accordance with its strong invasive 
potential, H1299 cells express high protein levels of vimen-
tin, but not of β-catenin, claudin-1, or AHR, as compared 
to the weakly invasive A549 cell line. E-cadherin, the pro-
totypical marker of epithelial cells, is largely expressed 
in A549, but not in H1299 cells, while ZO-1 and JAM-1 
protein levels were identical in H1299 and A549 cells. On 
the other hand, comparison of mRNA expression levels in 
H1299 and A549 cells revealed no significant differences 
in transcript levels of the aforementioned EMT markers 
except for E-cadherin and AHR. To further corroborate 
the above observations, we carried out mRNA and protein 
expression analysis of EMT biomarkers in two other cell 
lines, namely: CL1-0 and CL1-5, which are subclones iso-
lated from a 64-year-old man with lung adenocarcinoma 
(Chu et al. 1997). CL1-5, which is more aggressive in tran-
swell invasion assay than precancerous CL1-0 subclone, 
is E-cadherin deficient and instead expresses N-cadherin, 
while AHR expression is negligible. In contrast, vimentin 
is highly expressed in CL1-5 cells (supplementary Fig. 2). 
Taken together, these results indicate that AHR and/or 
vimentin expression levels strongly correlate with the inva-
sive potential of NSCLC cells. Specifically, downregulation 
of AHR leads to enhanced vimentin expression and EMT in 
NSCLC cells.
AHR overexpression results in a dramatic reduction 
of the invasive potential of H1299, both in vitro 
and in vivo
To validate the putative tumor suppressor-like function 
of AHR, H1299 cells were engineered to constitutively 
express wild-type AHR protein (H1299-AHR). In transwell 
invasion assays, the number of H1299-AHR cells migrat-
ing to Matrigel was reduced significantly as compared to 
H1299-wt (wild type) cells (Fig. 2a). No differences in cell 
morphology and proliferative curve were observed between 
H1299-wt and H1299-AHR (supplementary Fig. 3), sug-
gesting that the switch in invasive potential was unrelated 
to cell proliferation. The metastatic capacity of H1299-wt 
and H1299-AHR was evaluated in vivo by using lung colo-
nization assay. As compared to vehicle-injected control, a 
remarkable increase in the number of metastatic nodules 
on the lung surface was observed in the H1299-wt-treated 
group, whereas a decrease in the number of metastatic col-
onies was seen in the H1299-AHR-treated group (Fig. 2b). 
Thus, both in vivo and in vitro data demonstrate that AHR 
overexpression can suppress the invasiveness of NSCLC 
cells.
The expression of mesenchymal vimentin is reduced 
in AHR‑overexpressing H1299 cells
To determine the basis of AHR-mediated EMT suppres-
sion, the protein (or mRNA) expression levels of epithelial 
and mesenchymal biomarkers were examined. We found 
that AHR overexpression (as evidenced by a 9.92 ± 1.97- 
and 7.64 ± 1.71-fold increase in protein and mRNA lev-
els, respectively) significantly downregulates vimentin 
protein levels (0.42 ± 0.03-fold decrease, p < 0.001), but 
not mRNA levels as compared to H1299-wt (Fig. 3; supple-
mentary Fig. 4). The amounts of E-cadherin, N-cadherin, 
β-catenin, occludin, ZO-1, JAM-1, and claudin-1 are not 
altered on AHR overexpression, either at the protein or at 
mRNA level. These data indicate that AHR overexpression 
Table 1  Relationships between AHR expression and clinicopatho-
logical parameters of lung cancer
n AHR expression
Positive (%) Negative (%) p value
Total 30 18 (60) 12 (40)
 Age
  >60 13 9 (70) 4 (30) 0.366
  ≤60 17 9 (53) 8 (47)
 Gender
  Male 26 16 (62) 10 (38) 0.661
  Female 4 2 (50) 2 (50)
 Cell type
  Adenocarcinoma 7 4 (57) 3 (43) 0.064
  Squamous cell 
carcinoma
12 9 (75) 3 (25)
  Adenosquamous 
carcinoma
3 3 (100) 0 (0)
  Metastatic 
adenocarci-
noma
8 2 (25) 6 (75)
 Grade 0.878
  1 6 4 (67) 2 (33)
  2 11 6 (55) 5 (45)
  3 13 8 (62) 5 (38)
 TNM
  T1 1 0 (0) 1 (100) 0.09
  T2 19 14 (74) 5 (26)
  T3 10 4 (40) 6 (60)
  N0 9 5 (56) 4 (44) 0.88
  N1 9 6 (67) 3 (33)
  N2 12 7 (58) 5 (42)
  M0 22 16 (73) 6 (27) 0.018
  M1 8 2 (25) 6 (75)
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Fig. 1  The invasive potential of NSCLC cancer cell lines, A549 and 
H1299, is related to the amount of AHR protein expressed. a The 
invasive ability of A549 and H1299 was evaluated by using Matrigel-
precoated transwells as described in Materials and Methods. Both 
representative images and quantitative data demonstrated H1299 is 
more aggressive than A549. ***p < 0.001 indicates a statistically sig-
nificant difference from A549. b Representative images of immuno-
blot and agarose gel electrophoresis of PCR products to detect and 
compare protein and mRNA expression of epithelial–mesenchymal 
biomarkers between A549 and H1299 cells. At the mRNA level, 
besides AHR and E-cadherin, no differences were found between 
A549 and H1299. An inverse relationship was found between AHR 
protein expression level and vimentin. For HGNC name/symbol of 
genes and encoded proteins, please refer to Supplementary Table 1
Fig. 2  The invasive potential of H1299-AHR is reduced in vitro and 
in vivo. H1299-AHR (AHR-overexpressing H1299) was established 
as described in Materials and Methods. Representative photograph 
and quantitative data illustrate that the invasive potential of H1299-
AHR is reduced significantly in vitro (a) and in vitro (b). **p < 0.01 
and ***p < 0.001 indicate a statistically significant difference from 




can repress cell invasion through translational or post-
translational downregulation of vimentin.
Overexpressed AHR protein predominantly localizes 
in the cytosol, rather than the nucleus
The binding of B(a)P, a well-known exogenous AHR 
ligand, results in the rapid translocation of AHR into the 
nucleus where it functions as a transcriptional regulator 
and induces CYP1A1 and CYP1B1 expression. Accord-
ingly, an increase in CYP1A1 and CYP1B1 protein lev-
els is observed in both H1299-wt (4.93 ± 1.26- and 
2.50 ± 0.4-fold increase, respectively) and H1299-AHR 
cells (7.59 ± 2.31- and 5.61 ± 1.53-fold increase, respec-
tively) treated with 10 µM B(a)P as compared to untreated 
cells (Fig. 4a). To determine the subcellular distribution of 
overexpressed AHR, both immunofluorescent staining and 
nuclear fractionation methods were used. The FITC-stained 
AHR is located mainly in the cytosol of both H1299-wt and 
H1299-AHR cells in the absence of B(a)P; upon incuba-
tion with B(a)P, AHR translocates to the nucleus (Fig. 4b). 
This pattern of AHR localization was recapitulated in frac-
tionation studies wherein B(a)P treatment of H1299-wt or 
H1299-AHR reduces AHR levels in the cytosolic fraction 
and causes a concomitant increase in AHR levels in the 
nuclear fraction. This increase in nuclear AHR levels is 
further enhanced in B(a)P-treated H1299-AHR (Fig. 4c; 
supplementary Fig. 5). In comparison with groups without 
B(a)P treatment, B(a)P elicited a pronounced AHR N/C 
ratio (nuclear/cytosol AHR). Moreover, this ratio correlated 
with the induction of CYPs as well as XRE reporter activi-
ties (Fig. 4d). These data demonstrate that overexpressed 
and unliganded AHR predominantly resides in the cyto-
plasm, where it may bear a novel, tumor suppressor-like 
function and prevent EMT.
AHR–vimentin protein complex is formed in the 
cytoplasm resulting in proteasome degradation 
of vimentin
We observed that the reduction in vimentin protein expres-
sion in the presence of excess cytoplasmic AHR was 
accompanied by an increase in monomeric ubiquitin lev-
els, and therefore wanted to test whether the proteasome 
pathway was involved in this process. Treatment with 
MG-132 (10 μM; 26S proteasome inhibitor) for 6 h fully 
restored the vimentin level in H1299-AHR, suggesting the 
involvement of proteasome pathway in AHR-mediated 
vimentin degradation (Fig. 5a). AHR was previously iden-
tified as an E3 ubiquitin ligase (Ohtake et al. 2007, 2009). 
In this study, the formation of AHR–vimentin interacting 
complex was demonstrated by co-immunoprecipitation 
Fig. 3  The expression of mesenchymal vimentin is reduced in 
H1299-AHR. a Representative images of immunoblot and agarose 
gel electrophoresis of PCR products to detect and compare pro-
tein and mRNA expression of epithelial–mesenchymal biomarkers 
between H1299-wt and H1299-AHR. None of the detected genes is 
altered at the mRNA level, with the exception of AHR, which was 
overexpressed by transient transfection. At the protein level, among 
tested factors, AHR is augmented and vimentin is reduced signifi-




(Fig. 5b, c). In H1299-AHR cells, a fraction of AHR–
vimentin protein complex with poor poly-ubiquitination 
was captured using an antivimentin or anti-AHR antibody. 
MG-132 treatment not only increases the amount of cap-
tured AHR–vimentin complex, but also causes the accu-
mulation of ubiquitinated proteins, suggesting that AHR 
interaction with vimentin in the cytoplasm might facilitate 
vimentin ubiquitination, leading to proteasome-mediated 
degradation. On the other hand, in H1299-wt cells that 
poorly express AHR, it is intriguing to note that a small 
amount of AHR is capable of interacting strongly with 
vimentin and ubiquitinated proteins, especially when anti-
AHR capture antibody was used. These results suggest 
that a high turnover of vimentin takes place in H1299-wt 
to maintain its invasive potential.
AHR‑mediated vimentin degradation and EMT 
suppression are reversed when glycogen synthase 
kinase 3 beta (GSK3β) is inactivated
In malignant cancers, glycogen synthase kinase 3 beta 
(GSK3β) is inactivated, and this inactivation is known to 
promote cell migration and invasion. In H1299-AHR cells, 
a slight increase in GSK3β Ser-9 phosphorylation (repre-
sents inactive GSK3β) is observed, whereas the GSK3β 
Tyr-216 phosphorylation (represents active GSK3β), 
GSK3β protein level, and the GSK3β inactivation index 
(phospho-Ser-9/phospho-Tyr-216 ratio) are significantly 
unchanged, as compared to H1299-wt (Fig. 6a; supple-
mentary Fig. 7A). Treatment with CHIR-99021 (2 μM, 
GSK3β inhibitor) for 6 h not only inhibited Tyr-216 
Fig. 4  The overexpressed AHR protein predominantly localizes 
in the cytosol, rather than the nucleus. a Representative images and 
quantitative data illustrate the induction of CYP1A1 and CYP1B1 
after B(a)P (10 μM) treatment. In H1299-AHR, neither CYP1A1 nor 
CYP1B1 is induced. b Immunofluorescent staining shows the overex-
pressed AHR protein located mainly in the cytoplasm. In the absence 
of B(a)P treatment, no AHR nuclear translocation occurs. c The dis-
tribution of AHR was determined using nuclear fractionation. Quan-
titative data are presented in Supplementary Fig. 5. B(a)P treatment 
causes a pronounced AHR N/C ratio, in comparison with non-treated 
groups. d The transactivation of XRE reporter is detected in B(a)
P-treated groups (H1299-wt and H1299-AHR). In the absence of B(a)
P stimulation, the overexpressed AHR protein alone did not induce 
XRE reporter activities. **p < 0.01 and ***p < 0.001 indicate a sta-
tistically significant difference from H1299-wt; ##p < 0.01 indicates a 
statistically significant difference from H1299-wt treated with B(a)P
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phosphorylation completely (Fig. 6a), but also repressed 
AHR-mediated vimentin degradation (Fig. 6b) and inva-
sion prevention (Fig. 6c).
Silencing of AHR expression leads to EMT in A549 cells
A549-wt cells usually exhibit a pebble-like morphol-
ogy and strong intercellular adhesion. However, in A549-
shAHR cells (AHR-silenced A549), cell–cell contacts are 
degenerated and cells adopt a more elongated shape (sup-
plementary Fig. 8A), which is reminiscent of the morphol-
ogy of cells treated with TGF-β1 (an EMT inducer). In an 
in vitro invasion assay, a higher number of A549-shAHR-
invaded cells are obtained (supplementary Fig. 8B), sug-
gesting that AHR silencing might lead to the loss of 
tumor suppressor-like function and hence promote EMT. 
The epithelial–mesenchymal signatures of A549-wt and 
A549-shAHR are characterized in Fig. 7a. When AHR 
expression is knocked-down, A549-wt loses its epithe-
lial characteristics, as evidenced by an obvious reduction 
in E-cadherin, β-catenin, and claudin-1 protein levels and 
an increase (3.0 ± 0.58-fold) in mesenchymal vimen-
tin expression. This pattern is similar to the one seen in 
AHR-deficient H1299 cells (Fig. 1). However, the mRNA 
levels of these biomarkers are unaltered. Interestingly, 
AHR silencing strongly augments GSK3β Ser-9 phospho-
rylation (13.4 ± 4.4-fold increase) and simultaneously 
alleviates GSK3β Tyr-216 phosphorylation, resulting in an 
overt GSK3β inactivation index (phospho-Ser-9/phospho-
Tyr-216 ratio). The expression of GSK3β protein is also 
reduced. Taken together, these data clearly demonstrate that 
the AHR protein resident in the cytoplasm can prevent the 
expression of mesenchymal markers and downregulate can-
cer cell metastasis.
Discussion
In mammals, AHR is almost ubiquitously expressed among 
organs, but its expression levels vary widely. The highest 
levels are detected in the liver, lungs, and kidneys, as well 
as most of the cells of epithelial origin. Therefore, we can 
speculate AHR possesses physiological functions besides 
metabolism. AHR-null mice phenotypically exhibit devel-
opmental and functional deficits in several tissues (Harstad 
et al. 2006; Singh et al. 2011; Stevens et al. 2009). Accumu-
lating in vitro studies also provide substantial support for 
AHR involvement in cell proliferation (Abdelrahim et al. 
2003), apoptosis (Fan et al. 2010), cell migration (Carva-
jal-Gonzalez et al. 2009b), immune regulation (Navid et al. 
2013), and cancer progression (Safe et al. 2013).
AHR-expression levels, at least in some tumors, are cor-
related with poor differentiation and prognosis clinically. 
However, in other tumors, an inverse correlation is found, 
which suggests that the role of AHR during progression of 
different tumors is complicated (Portal-Nuñez et al. 2012). 
Fig. 5  AHR–vimentin protein complex is formed in the cytoplasm 
and results in proteasome degradation of vimentin. a Representa-
tive images and quantitative data show that AHR-mediated vimen-
tin degradation can be rescued by MG-132 (26S proteasome inhibi-
tor) treatment. In addition, monomeric ubiquitin levels increase in 
H1299-AHR. ***p < 0.001 indicates a statistically significant dif-
ference from H1299-wt; ###p < 0.001 indicates a statistically sig-
nificant difference from H1299-AHR. b/c Co-immunoprecipitation 
studies demonstrate the formation of AHR–vimentin protein complex 
in cytoplasm. IgG is used as loading control. In H1299-AHR group, 
an inferior signal of ubiquitinated proteins is detected, whereas this 
signal is enhanced in H1299-AHR group treated with MG-132, sug-
gesting that the AHR–vimentin interacting complex might facilitate 
vimentin poly-ubiquitination and vimentin proteasome degradation. 
However, in H1299-wt group, although the AHR-expression level is 
weak, the small amount of AHR still shows a strong interaction with 
vimentin, as well as poly-ubiquitinated proteins, which suggests a 
frequent renewal of vimentin
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Generally, cytoplasmic AHR and nuclear AHR are predom-
inantly observed in non-neoplastic tissues and in malignant 
tissues, respectively (Ishida et al. 2015). Ligand binding 
alters AHR conformation to expose its nuclear localiza-
tion sequence (NLS), which results in nuclear import. After 
that, the activated AHR is eliminated either by nuclear 
exportation and ubiquitin–proteasome degradation or by 
its negative feedback repressor (Ikuta et al. 2009; Stevens 
et al. 2009). Thus, the accumulation of AHR in the nuclei 
of malignant tumors can be attributed to the following 
abnormalities: the aberrant activation of transcriptional 
regulators [such as protein kinase CK2, signal transducer, 
and activator of transcription 6 (STAT6) and NFκB] that 
enhance AHR expression (Belguise et al. 2007); obstruc-
tions in the negative feedback loop; and most impor-
tantly, constitutive AHR activation (even in the absence of 
ligands). Expression of constitutively active AHR in vivo 
heightens the susceptibility to neoplastic lesions (Anders-
son et al. 2002; Moennikes et al. 2004) and facilitates the 
differentiation of Treg cells (Navid et al. 2013). These data 
Fig. 6  AHR-mediated vimentin degradation and EMT inhibition 
are reversed when GSK3β is inactivated. a Representative images 
and quantitative data show the intensity of GSK3β phosphorylation 
on Ser-9 or Tyr-216 residues. CHIR-99021 (GSK3β inhibitor, 2 μM) 
treatment of H1299-AHR for 6 h completely inhibits Tyr-216 phos-
phorylation of GSK3β. b CHIR-99021 treatment rescues AHR-medi-
ated vimentin degradation. c Representative images and quantitative 
data show CHIR-99021 treatment reverses AHR-mediated invasion 
prevention. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate a sta-
tistically significant difference from the control group (H1299-wt); 




demonstrate that nuclear AHR is a potent oncogenic fac-
tor. In this study, we corroborated that NSCLC cells with 
abundant AHR in the cytoplasm (e.g., A549, H1299-AHR, 
CL1-0) are poorly invasive, whereas invasive potential is 
enhanced in AHR-deficient cells (such as A549-shAHR, 
H1299-wt, CL1-5). Similar results were also obtained in 
neuroblastoma, where ectopic expression of AHR was 
found to downregulate MYCN (specific malignant factor of 
neuroblastoma) and E2F1 expression and correlated highly 
with the histological grade of differentiation. Induction of 
MYCN and E2F1 expression was observed when AHR is 
silenced (Wu et al. 2014). Collectively, these data prove 
Fig. 7  Malignant characteristics develop in AHR-silenced A549 
cells. A549-shAHR (AHR-silenced A549) was established as 
described in Materials and Methods. a Representative images of 
immunoblot and agarose gel electrophoresis of PCR products to 
detect and compare protein and mRNA expression of epithelial–mes-
enchymal biomarkers between A549-wt and A549-shAHR. None of 
the detected genes is altered at the mRNA level, with the exception of 
AHR, which was silenced by shRNA. However, the protein expres-
sion levels of E-cadherin, β-catenin, and claudin-1 are markedly 
reduced, whereas vimentin expression increases. b AHR knock-down 
causes a strong augmentation in GSK3β Ser-9 phosphorylation, and 
an alleviation in GSK3β Tyr-216 phosphorylation, which results in an 
overt GSK3β inactivation index. The GSK3β protein level is reduced 
in A549-shAHR. These data demonstrate that the cytoplasm-residing 
AHR functions as a guard and prevents the expression of mesenchy-
mal factors. **p < 0.01 and ***p < 0.001 indicate a statistically sig-
nificant difference from the control group
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that AHR-expression level is inversely correlated with 
malignancy, especially EMT, in various cancer cells.
In many types of cancer, the existence of AHR ago-
nists has been demonstrated that can augment the expres-
sion of inflammatory mediators (Miller et al. 2005), MMPs 
(Peng et al. 2009a; Ishida et al. 2010), and transcriptional 
regulators (Pierre et al. 2014) in a genomic pathway, which 
leads to downregulation of cell adhesion and upregula-
tion of migration and invasion. However, in this study, the 
repression of invasiveness in H1299-AHR was a result of 
a decrease in vimentin content. In contrast, the amount 
of vimentin increased markedly in A549-shAHR cells, 
thereby increasing the invasive potential of these cells. A 
reduction in the expression of E-cadherin, β-catenin, and 
claudin-1 also contributed to EMT in A549-shAHR. Impor-
tantly, these changes were limited to the protein level, 
while mRNA content was unchanged. In H1299-AHR, 
vimentin degradation could be abrogated by proteasome 
inhibition, which suggests that unliganded AHR residing 
in the cytoplasm can accelerate vimentin degradation in 
a non-genomic manner. In addition to its role as a ligand-
activated transcription factor, AHR has also been identi-
fied as a novel E3 ubiquitin ligase, which facilitates the 
assembling of ubiquitin ligase complex and accelerates 
proteolysis of certain nuclear receptors (Ohtake et al. 2007, 
2009). AHR has been found to suppress intestinal carcino-
genesis through E3 ubiquitin ligase-dependent β-catenin 
degradation (Kawajiri et al. 2009). In this study, by using 
co-immunoprecipitation assay, we found that cytoplas-
mic AHR could interact with vimentin, followed by an 
increase in poly-ubiquitination, eventually leading to pro-
tein degradation.
The activation of AHR via a non-genomic pathway has 
been attracting interest in EMT regulation. For example, 
phthalates-stimulated AHR couples with G proteins and trig-
gers the PI-3 kinase/Akt/NF-κB and ERK/VEGF cascades, 
which contributes to metastasis and angiogenesis, respec-
tively (Tsai et al. 2014). The Src kinase, an important factor 
in maintenance of cadherin-dependent intercellular contact, is 
also known to be associated with AHR complex. Hexachlo-
robenzene treatment immediately dissociates Src kinase from 
AHR, thereby activating its own kinase activity and destabi-
lizing cell adhesion (Randi et al. 2008). In cultured fibroblasts 
derived from AHR−/− mice, an enhanced spreading and adhe-
sion correlate with decreased Vav-3 and Rac1 activities and 
increased RhoA/Rho kinase (Rock) pathway activity (Carva-
jal-Gonzalez et al. 2009a, b). These findings demonstrate that 
multiple signaling factors can be regulated by AHR through 
a non-genomic pathway. In this work, we found that cyto-
plasmic AHR can regulate GSK3β signaling. GSK3β activa-
tion usually induces phosphorylation of its substrates (e.g., 
β-catenin and cyclin D1), thus promoting ubiquitination and 
proteasome degradation of these substrates. The inactiva-
tion of GSK3β has been identified as an important event in 
cancer progression (Mishra et al. 2015). In this study, pro-
nounced phosphorylation and de-phosphorylation of GSK3β 
Ser-9 and Tyr-216 residues, respectively, were observed in 
A549-shAHR cells, suggesting that the loss of AHR predis-
poses to GSK3β inactivation. Endogenous GSK3 activity 
is required for maintenance of the integrity of apical junc-
tion complexes, whereas the reduction of GSK3 activity will 
result in decreased protein level of claudin-1 and E-cadherin, 
but without influencing on ZO-1 and JAM-1 (Severson et al. 
2010), which is similar to what we found in A549-shAHR. 
Although AHR overexpression has no effect on GSK3β inac-
tivation index in H1299-AHR, treatment with GSK3β inhibi-
tor did prevent vimentin degradation and restored invasive 
potential. These data suggest that the relative level of AHR 
in the cytoplasm is crucial for the maintenance of GSK3β in 
active form, as the downregulation of AHR expression results 
in GSK3β inactivation and EMT.
The role of AHR in tumor pathology is complicated and 
not fully understood yet. In this work, we showed that an 
inverse relationship exists between AHR protein levels and 
the invasive ability of NSCLC cells. We have demonstrated 
for the first time that the cytoplasm-residing, unliganded 
AHR protein functions as a guard and prevents the expres-
sion of mesenchymal factors. Through its E3 ligase activity, 
AHR maintains GSK3β in an active form and accelerates 
vimentin degradation, thus suppressing invasive behav-
ior and EMT via a non-genomic pathway. Although AHR 
in cytoplasm possesses tumor suppressor-like function, 
unfortunately, it is also likely to act as a potent inducer of 
malignancy. The presence of AHR agonists will trigger 
AHR translocation into the nucleus, where it can activate a 
genomic pathway favoring tumor survival and progression 
(supplementary Fig. 9). Thus, AHR may be an attractive 
target with dual effects during cancer treatment.
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